Literature DB >> 19738465

Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.

Kyra Chua1, Benjamin P Howden.   

Abstract

PURPOSE OF REVIEW: The role of vancomycin for treating serious methicillin-resistant Staphylococcus aureus infections and the optimal method of administration of anti-Gram-positive antibiotics have been recently questioned. This review summarizes the current literature concerning the use of vancomycin and the role of continuous infusion antimicrobials for treatment of Gram-positive infections. RECENT
FINDINGS: Although vancomycin-resistant S. aureus due to acquisition of vanA from vancomycin-resistant enterococci remains rare (11 cases to date), heterogeneous vancomycin-intermediate S. aureus and vancomycin-intermediate S. aureus have now been reported from many countries around the world. Laboratory studies have demonstrated subtle, but potentially significant differences in vancomycin susceptibility depending on the methods used, meaning clinicians need to liaise closely with their local microbiology laboratories. Higher vancomycin minimum inhibitory concentrations within the accepted susceptible range and the presence of vancomycin-intermediate S. aureus are associated with vancomycin treatment failure. It is likely that heterogeneous vancomycin-intermediate S. aureus contributes to treatment failure in patients with serious, high bacterial load infections. Despite the potential limitations of vancomycin, no clinical trials have demonstrated superiority of alternative agents.Administration of antibiotics by continuous infusion is supported by in-vitro and animal studies for the classes of antibiotic that demonstrate time-dependent killing. However, few, limited clinical studies have been performed to date.
SUMMARY: Vancomycin remains an important first-line antimicrobial for treatment of serious methicillin-resistant S. aureus infections; however, a detailed analysis of isolate susceptibility and appropriate dosing are important. Although continuous infusion of some anti-Gram-positive antimicrobials may provide theoretical benefits, clinical trials demonstrating superiority in outcomes are uncommon. Use of continuous infusion may, however, provide practical advantages in patients on home intravenous antibiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738465     DOI: 10.1097/QCO.0b013e328331fbcd

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

1.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

2.  Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.

Authors:  Sheryl Zelenitsky; Noha Alkurdi; Zhanni Weber; Robert Ariano; George Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

3.  Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use.

Authors:  Fawziah Marra; David M Patrick; Mei Chong; Rachel McKay; Linda Hoang; William R Bowie
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

4.  Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.

Authors:  Sebastiaan J van Hal; Mark Jones; Iain B Gosbell; David L Paterson
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

5.  Emerging antimicrobial resistance in early and late-onset neonatal sepsis.

Authors:  Lamiaa Mohsen; Nermin Ramy; Dalia Saied; Dina Akmal; Niveen Salama; Mona M Abdel Haleim; Hany Aly
Journal:  Antimicrob Resist Infect Control       Date:  2017-06-13       Impact factor: 4.887

6.  Zinc-binding to the cytoplasmic PAS domain regulates the essential WalK histidine kinase of Staphylococcus aureus.

Authors:  Ian R Monk; Nausad Shaikh; Stephanie L Begg; Mike Gajdiss; Liam K R Sharkey; Jean Y H Lee; Sacha J Pidot; Torsten Seemann; Michael Kuiper; Brit Winnen; Rikki Hvorup; Brett M Collins; Gabriele Bierbaum; Saumya R Udagedara; Jacqueline R Morey; Neha Pulyani; Benjamin P Howden; Megan J Maher; Christopher A McDevitt; Glenn F King; Timothy P Stinear
Journal:  Nat Commun       Date:  2019-07-11       Impact factor: 14.919

7.  Vancomycin Ophthalmic Ointment 1% for methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis infections: a case series.

Authors:  Chie Sotozono; Masahiko Fukuda; Masao Ohishi; Keiko Yano; Hideki Origasa; Yoshinori Saiki; Yoshikazu Shimomura; Shigeru Kinoshita
Journal:  BMJ Open       Date:  2013-01-29       Impact factor: 2.692

8.  Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Authors:  Arpasiri Srisrattakarn; Chonthicha Chaiyapoke; Sirikarn Booncharoen; Sujintana Wongthong; Aroonwadee Chanawong; Patcharaporn Tippayawat; Ratree Tavichakorntrakool; Aroonlug Lulitanond
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.